Starting at a higher price for a small number of MDR combo pts. and maybe TNBC pts in 2020 to account for lower patient volume initially is not unreasonable. To capture the mono HIV market and mass use in cancer if approved, it would make sense to then drop the price substantially after that.

NP may just be referring to initial pricing in this first subset of patients to generate meaningful revenue in 2020.